Botulinum toxin A administered as doses of 50, 100, 150, 200 or 300U in patients with overactive bladder and urge urinary incontinence

Trial Profile

Botulinum toxin A administered as doses of 50, 100, 150, 200 or 300U in patients with overactive bladder and urge urinary incontinence

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2012

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Overactive bladder; Urge incontinence
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Aug 2012 Results published in the International Urogynecology Journal.
    • 01 Apr 2011 Results published in Neurourology and Urodynamics.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top